 <h1>Reno-M-60 Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>diatrizoate</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about diatrizoate. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Reno-M-60.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to diatrizoate: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, diatrizoate (the active ingredient contained in Reno-M-60) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking diatrizoate:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Blood in the urine</li>
<li>convulsions</li>
<li>cough</li>
<li>decrease in the amount of urine</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>hives, itching, or rash</li>
<li>not able to pass urine</li>
<li>pain or burning while urinating</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>shortness of breath</li>
<li>tightness in the chest</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to diatrizoate: injectable powder for injection, injectable solution, oral powder for reconstitution, oral and rectal solution</i></p><h3>General</h3><p>The most frequently reported adverse reactions were vomiting, nausea, diarrhea, erythema, a sensation of pain, and a general feelings of warmth on intravascular administration.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Common (1% to 10%) Transient disturbance in heart rate, blood pressure, disturbance in cardiac rhythm or function, cardiac arrest</p>
<p><b>Uncommon</b> (0.1% to 1%): Thrombophlebitis, venous thrombosis</p>
<p><b>Rare</b> (0.01% to 0.1%): Thromboembolic events, myocardial infarction</p>
<p><b>Very rare</b> (less than 0.01%): Severe hypotension and collapse; circulatory failure; ventricular fibrillation</p>
<p><b>Frequency not reported</b>: Tachycardia, shock, hypotension, hypertension, reflex tachycardia, cyanosis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomit, diarrhea</p>
<p><b>Frequency not reported</b>: Diarrhea (ceases as soon as the intestine has been emptied); existing enteritis or colitis may be temporarily exacerbated; in case of obstruction, the prolonged contact with bowel mucosa can lead to erosions and to bowel necrosis; intestinal perforation; abdominal pain; oral mucosal blistering<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Anaphylactoid reactions (mild angioedema, conjunctivitis, coughing pruritus, rhinitis, sneezing, urticarial)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Transient disturbances in respiratory rate, dyspnea, respiratory distress, cough</p>
<p><b>Rare</b> (less than 0.1%): Respiratory arrest, pulmonary edema</p>
<p><b>Frequency not reported</b>: Bronchospasm, medication aspiration, pulmonary edema following aspiration, aspiration pneumonia, sneezing, laryngeal spasm<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Thyroid function tests indicative of hypothyroidism or transient thyroid suppression in adults and pediatric patients (including infants)</p>
<p><b>Frequency not reported</b>: Hyperthyroidism<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Rare</b> (less than 0.1%): Toxic epidermal necrolysis, urticaria, rash, pruritus, erythema, face edema, mucocutaneous syndrome (e.g.  Stevens-Johnson's or Lyell syndrome)</p>
<p><b>Frequency not reported</b>: Sweating, mild angioedema<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very rare</b> (less than 0.01%): Convulsions, cerebral symptoms</p>
<p><b>Frequency not reported</b>: Disturbances in consciousness, dizziness, headache, tremor, somnolence, transient paresis (vision or facial muscle paresis and epileptic fits), amnesia, photophobia, temporary states of agitation or confusion<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Perforation of the urethra, genitourinary tract infections, oliguria, hematuria, anuria<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Local pain, edema<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Fluid and electrolyte imbalance<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Lacrimation, temporary blindness<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Pyrexia, sweating, chills, blanching, weakness, gagging and feeling suffocated, gasping, edema, cramp, malaise<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Temporary renal failure<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Reno-M-60 (diatrizoate)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: ionic iodinated contrast media</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Cystografin, Cystografin-Dilute, Hypaque Meglumine, Reno-30, ... +2 more</dd></dl>
<h3>Professional resources</h3>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Diagnosis and Investigation</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to diatrizoate: injectable powder for injection, injectable solution, oral powder for reconstitution, oral and rectal solution</i></p><h3>General</h3><p>The most frequently reported adverse reactions were vomiting, nausea, diarrhea, erythema, a sensation of pain, and a general feelings of warmth on intravascular administration.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Common (1% to 10%) Transient disturbance in heart rate, blood pressure, disturbance in cardiac rhythm or function, cardiac arrest</p><p><b>Uncommon</b> (0.1% to 1%): Thrombophlebitis, venous thrombosis</p><p><b>Rare</b> (0.01% to 0.1%): Thromboembolic events, myocardial infarction</p><p><b>Very rare</b> (less than 0.01%): Severe hypotension and collapse; circulatory failure; ventricular fibrillation</p><p><b>Frequency not reported</b>: Tachycardia, shock, hypotension, hypertension, reflex tachycardia, cyanosis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomit, diarrhea</p><p><b>Frequency not reported</b>: Diarrhea (ceases as soon as the intestine has been emptied); existing enteritis or colitis may be temporarily exacerbated; in case of obstruction, the prolonged contact with bowel mucosa can lead to erosions and to bowel necrosis; intestinal perforation; abdominal pain; oral mucosal blistering<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Anaphylactoid reactions (mild angioedema, conjunctivitis, coughing pruritus, rhinitis, sneezing, urticarial)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Transient disturbances in respiratory rate, dyspnea, respiratory distress, cough</p><p><b>Rare</b> (less than 0.1%): Respiratory arrest, pulmonary edema</p><p><b>Frequency not reported</b>: Bronchospasm, medication aspiration, pulmonary edema following aspiration, aspiration pneumonia, sneezing, laryngeal spasm<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Thyroid function tests indicative of hypothyroidism or transient thyroid suppression in adults and pediatric patients (including infants)</p><p><b>Frequency not reported</b>: Hyperthyroidism<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Rare</b> (less than 0.1%): Toxic epidermal necrolysis, urticaria, rash, pruritus, erythema, face edema, mucocutaneous syndrome (e.g.  Stevens-Johnson's or Lyell syndrome)</p><p><b>Frequency not reported</b>: Sweating, mild angioedema<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very rare</b> (less than 0.01%): Convulsions, cerebral symptoms</p><p><b>Frequency not reported</b>: Disturbances in consciousness, dizziness, headache, tremor, somnolence, transient paresis (vision or facial muscle paresis and epileptic fits), amnesia, photophobia, temporary states of agitation or confusion<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Perforation of the urethra, genitourinary tract infections, oliguria, hematuria, anuria<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Local pain, edema<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Fluid and electrolyte imbalance<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Lacrimation, temporary blindness<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Pyrexia, sweating, chills, blanching, weakness, gagging and feeling suffocated, gasping, edema, cramp, malaise<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Temporary renal failure<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about Reno-M-60 (diatrizoate)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: ionic iodinated contrast media</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diagnosis and Investigation</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>